Bryan Dechairo Sells 3,413 Shares of GeneDx (NASDAQ:WGS) Stock

GeneDx Holdings Corp. (NASDAQ:WGS) COO Bryan Dechairo sold 3,413 shares of the company’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $99.53, for a total value of $339,695.89. Following the transaction, the chief operating officer directly owned 5,961 shares in the company, valued at $593,298.33. This represents a 36.41% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

GeneDx Stock Performance

WGS opened at $85.35 on Thursday. The company has a market cap of $2.47 billion, a P/E ratio of 948.33 and a beta of 2.00. The company has a quick ratio of 2.59, a current ratio of 2.71 and a debt-to-equity ratio of 0.18. The firm’s 50-day moving average price is $129.42 and its 200-day moving average price is $124.86. GeneDx Holdings Corp. has a 52-week low of $55.17 and a 52-week high of $170.87.

Hedge Funds Weigh In On GeneDx

Several institutional investors have recently made changes to their positions in the company. Rhumbline Advisers lifted its holdings in GeneDx by 42.7% during the second quarter. Rhumbline Advisers now owns 27,610 shares of the company’s stock valued at $2,549,000 after purchasing an additional 8,258 shares in the last quarter. Legal & General Group Plc raised its position in shares of GeneDx by 55.9% during the 2nd quarter. Legal & General Group Plc now owns 22,271 shares of the company’s stock worth $2,056,000 after purchasing an additional 7,987 shares during the last quarter. Y Intercept Hong Kong Ltd purchased a new position in GeneDx in the 2nd quarter valued at about $589,000. Legal Advantage Investments Inc. lifted its stake in GeneDx by 19.8% in the 2nd quarter. Legal Advantage Investments Inc. now owns 60,600 shares of the company’s stock valued at $5,594,000 after buying an additional 10,000 shares in the last quarter. Finally, Slow Capital Inc. acquired a new stake in GeneDx in the 2nd quarter worth about $3,614,000. 61.72% of the stock is owned by hedge funds and other institutional investors.

Key GeneDx News

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: Analyst sentiment remains constructive — several firms maintain Buy/Upgraded ratings and the consensus is a “Moderate Buy,” which supports medium‑term upside. Analyst Consensus
• Neutral Sentiment: Company scheduled to report Q4 2025 results on Feb 23, 2026 — a clear near‑term catalyst that can either amplify a rebound or deepen the decline depending on results and guidance. Q4 2025 Release Date
• Negative Sentiment: Clustered insider selling by senior executives: COO Bryan Dechairo sold 3,413 shares (~$339.7k) and CEO Katherine Stueland sold 1,653 shares; the CFO also sold 317 shares — these C‑suite sales can signal reduced near‑term insider conviction and weigh on investor sentiment. COO Sale CEO Sale CFO Sale
• Negative Sentiment: Technical and flow factors look unfavorable: shares are trading well below recent 50‑day and 200‑day averages and turnover is elevated versus normal volume — these conditions often trigger momentum selling and increase volatility. Price & Technicals

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. BTIG Research raised their target price on GeneDx from $165.00 to $200.00 and gave the stock a “buy” rating in a research note on Friday, December 12th. Wall Street Zen raised GeneDx from a “hold” rating to a “buy” rating in a report on Saturday, January 31st. Guggenheim reiterated a “buy” rating and issued a $170.00 target price (up previously from $115.00) on shares of GeneDx in a research report on Wednesday, October 29th. Wells Fargo & Company set a $155.00 price target on shares of GeneDx and gave the stock an “equal weight” rating in a research report on Monday, December 15th. Finally, Canaccord Genuity Group lifted their price objective on shares of GeneDx from $160.00 to $170.00 and gave the company a “buy” rating in a research note on Monday, December 22nd. Six investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, GeneDx currently has an average rating of “Moderate Buy” and a consensus target price of $138.13.

GeneDx Company Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.